Unlocking Precision Medicine in Refractory Multiple Myeloma

Description

Resistance to therapy remains a significant challenge in multiple myeloma, often driven by the substantial genetic heterogeneity inherent to this disease. This now includes resistance to state-of-the-art immunotherapies targeting BCMA. To address this critical challenge, we propose to develop a novel, multi-agent therapeutic strategy designed to overcome resistance and improve outcomes for patients with relapsed or refractory MM who have exhausted current treatment options, including the most advanced immunotherapies. Our approach utilizes functional genomic screens and high-throughput combinatorial drug screening platforms to identify synergistic drug combinations effective against treatment-resistant MM. We aim to generate robust preclinical data to support the rapid initiation of human clinical trials and ultimately translate these findings into improved clinical outcomes for patients with relapsed or refractory disease.